JP2013530239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530239A5 JP2013530239A5 JP2013518695A JP2013518695A JP2013530239A5 JP 2013530239 A5 JP2013530239 A5 JP 2013530239A5 JP 2013518695 A JP2013518695 A JP 2013518695A JP 2013518695 A JP2013518695 A JP 2013518695A JP 2013530239 A5 JP2013530239 A5 JP 2013530239A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- halo
- substituted
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- -1 morpholino, piperazinyl Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 0 *c1nc(*C([C@](*=**=S)C(*)=N2)C(*)=C2I)n[s]1 Chemical compound *c1nc(*C([C@](*=**=S)C(*)=N2)C(*)=C2I)n[s]1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36026210P | 2010-06-30 | 2010-06-30 | |
| US61/360,262 | 2010-06-30 | ||
| PCT/US2011/042531 WO2012003278A1 (en) | 2010-06-30 | 2011-06-30 | Quinolines as p13k inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013530239A JP2013530239A (ja) | 2013-07-25 |
| JP2013530239A5 true JP2013530239A5 (enExample) | 2014-08-14 |
Family
ID=44359353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518695A Withdrawn JP2013530239A (ja) | 2010-06-30 | 2011-06-30 | Ｐｉ３ｋ阻害剤としてのキノリン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8686137B2 (enExample) |
| EP (1) | EP2588477A1 (enExample) |
| JP (1) | JP2013530239A (enExample) |
| AU (1) | AU2011272857A1 (enExample) |
| CA (1) | CA2803619A1 (enExample) |
| MX (1) | MX2012014983A (enExample) |
| WO (1) | WO2012003278A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| KR20170082490A (ko) | 2014-07-04 | 2017-07-14 | 루핀 리미티드 | Pi3k 억제제로서 퀴놀리지논 유도체 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2132545B1 (enExample) * | 1971-04-08 | 1974-08-02 | Roussel Uclaf | |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| DE3020458C2 (de) | 1980-05-29 | 1986-07-31 | Herzog, Thomas, Prof. Dr., 3500 Kassel | Vorgehängte Fassaden-, Bau- oder Dekorationsplatte |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| US6355636B1 (en) | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| CA2738429C (en) * | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| GB0821693D0 (en) | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
-
2011
- 2011-06-30 WO PCT/US2011/042531 patent/WO2012003278A1/en not_active Ceased
- 2011-06-30 AU AU2011272857A patent/AU2011272857A1/en not_active Abandoned
- 2011-06-30 JP JP2013518695A patent/JP2013530239A/ja not_active Withdrawn
- 2011-06-30 US US13/701,772 patent/US8686137B2/en not_active Expired - Fee Related
- 2011-06-30 MX MX2012014983A patent/MX2012014983A/es not_active Application Discontinuation
- 2011-06-30 CA CA2803619A patent/CA2803619A1/en not_active Abandoned
- 2011-06-30 EP EP11730847.8A patent/EP2588477A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533883A5 (enExample) | ||
| JP2013530236A5 (enExample) | ||
| JP2013533884A5 (enExample) | ||
| JP2013530238A5 (enExample) | ||
| JP2013530239A5 (enExample) | ||
| JP2016518385A5 (enExample) | ||
| HRP20140147T1 (hr) | 3-supstituirani derivati hinolina ili hinoksalina i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k) | |
| JP2015536307A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| KR102717072B1 (ko) | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 | |
| JP2017512833A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| JP2015527401A5 (enExample) | ||
| SI2704721T1 (en) | ACTIVATORS PIANO KINASE FOR USE IN THERAPY | |
| AR081448A1 (es) | DERIVADOS DE BENCIMIDAZOL E IMIDAZO[1,2-A]PIRIDINA, COMPOSICION FARMACEUTICA QUE LOS CONTIENE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR DISFUNCION DE PI3Kd | |
| JP2011529073A5 (enExample) | ||
| JP2013542996A5 (enExample) | ||
| JP2010280669A5 (enExample) | ||
| JP2016510758A5 (enExample) | ||
| RU2016115082A (ru) | Замещенные аминопиримидиновые соединения и способы их использования | |
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| ME02754B (me) | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme | |
| JP2014508753A5 (enExample) | ||
| JP2013522316A5 (enExample) |